Reduced Incidence of Carbapenem-Resistant Klebsiella pneumoniae Infections in Cardiac Surgery Patients after Implementation of an Antimicrobial Stewardship Project.
Klebsiella
postoperative infections
stewardship
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
28 08 2019
28 08 2019
Historique:
received:
13
08
2019
revised:
23
08
2019
accepted:
26
08
2019
entrez:
31
8
2019
pubmed:
31
8
2019
medline:
31
8
2019
Statut:
epublish
Résumé
Infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) are associated with increased mortality in cardiac surgery patients. In this short communication, we report on the changes in the incidence of CR-Kp colonization and CR-Kp infection in cardiac surgery patients from 2014 to 2018 in a teaching hospital in Italy, after the implementation of an antimicrobial stewardship project in 2014. During the study period, 2261 patients underwent open-heart surgery. Of them, 130 were found to be colonized by CR-Kp (5.7%) and 52 developed a postoperative CR-Kp infection (2.3%). The crude in-hospital mortality in patients with CR-Kp infections was 48% (25/52). The incidences of both CR-Kp colonization (incidence rate ratio (IRR) 0.82, 95% confidence intervals (CI) 0.78-0.86, p < 0.001) and CR-Kp infection (IRR 0.76, 95% CI 0.69-0.83, p < 0.001) considerably decreased over the study period. This encouraging result should prompt further concerted efforts, directed towards retaining the positive impact of stewardship and infection-control interventions on CR-Kp-related morbidity in the long term.
Identifiants
pubmed: 31466372
pii: antibiotics8030132
doi: 10.3390/antibiotics8030132
pmc: PMC6783823
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
D.R.G. reports, outside the submitted work, grants from MSD Italia and honoraria from Stepstone Pharma GmbH. C.V. reports, outside of this work, received speaker’s and advisory board fees from Merck Sharp and Dohme, Gilead Sciences, Forrest Italia, Angelini, and Pfizer Inc. The other authors have no conflict of interests to disclose.
Références
Am J Transplant. 2015 Jun;15(6):1708-15
pubmed: 25754742
J Antimicrob Chemother. 2015 Jul;70(7):2133-43
pubmed: 25900159
BMC Infect Dis. 2015 Oct 13;15:415
pubmed: 26464061
Interact Cardiovasc Thorac Surg. 2016 Nov;23(5):762-768
pubmed: 27371609
Antimicrob Resist Infect Control. 2019 Jan 10;8:8
pubmed: 30651974
Infection. 2017 Dec;45(6):849-856
pubmed: 28856589
Front Med (Lausanne). 2019 Apr 16;6:74
pubmed: 31041313
Eur J Clin Microbiol Infect Dis. 2017 Apr;36(4):663-669
pubmed: 27909821
Eur J Cardiothorac Surg. 2019 Apr 1;55(4):760-765
pubmed: 30307552